Details for Patent: 8,377,474
✉ Email this page to a colleague
Which drugs does patent 8,377,474 protect, and when does it expire?
Patent 8,377,474 protects RYTARY and is included in one NDA.
This patent has twenty-five patent family members in twelve countries.
Summary for Patent: 8,377,474
Title: | Controlled release formulations of levodopa and uses thereof |
Abstract: | The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor. |
Inventor(s): | Hsu; Ann (Los Altos Hills, CA), Kou; Jim H. (San Jose, CA), Alani; Laman (Hillsborough, CA) |
Assignee: | Impax Laboratories, Inc. (Hayward, CA) |
Application Number: | 12/599,668 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,377,474 |
Patent Claim Types: see list of patent claims | Composition; Formulation; Compound; Use; Dosage form; |
Drugs Protected by US Patent 8,377,474
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Impax Labs Inc | RYTARY | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 203312-001 | Jan 7, 2015 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF PARKINSON'S DISEASE | ⤷ Try a Trial | |||
Impax Labs Inc | RYTARY | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 203312-001 | Jan 7, 2015 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION | ⤷ Try a Trial | |||
Impax Labs Inc | RYTARY | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 203312-002 | Jan 7, 2015 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF PARKINSON'S DISEASE | ⤷ Try a Trial | |||
Impax Labs Inc | RYTARY | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 203312-002 | Jan 7, 2015 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION | ⤷ Try a Trial | |||
Impax Labs Inc | RYTARY | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 203312-003 | Jan 7, 2015 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF PARKINSON'S DISEASE | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,377,474
PCT Information | |||
PCT Filed | December 26, 2008 | PCT Application Number: | PCT/US2008/014080 |
PCT Publication Date: | July 09, 2009 | PCT Publication Number: | WO2009/085306 |
International Family Members for US Patent 8,377,474
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2008343787 | ⤷ Try a Trial | |||
Canada | 2711014 | ⤷ Try a Trial | |||
China | 101910113 | ⤷ Try a Trial | |||
European Patent Office | 2234963 | ⤷ Try a Trial | |||
Spain | 2804348 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |